Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 2.1¢ | Day High | 2.1¢ | Day Low | 1.9¢ | |||
| Daily Volume | 6390568 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 23 | 1.9¢ | 3337643 | 5 | 2.1¢ | 1075545 | |
| Dr. Steven Gourlay | Chief Executive Officer, Managing Director, Executive Director |
| Mr. William Souter | Chief Financial Officer |
| Ms. Cheryl Townsend | Vice President of Clinical Operations |
| Mr. Michael Roberts | Head of Investor Relations and Comms |
| Dr. Dana C. Hilt | Chief Medical Officer |
| Ms. Fujun Li | Head of Manufacturing |
| Mr. Andrew Udell | Chief Commercial Officer |
| Mr. Peter Gordon Webse | Company Secretary |
| Dr. Geoffrey E. D. Brooke | Non-Executive Chairman of the Board |
| Mr. Malcolm John Mccomas | Non-Executive Director |
| Mr. George Morstyn | Non-Executive Director |
| Dr. Nicki J. Vasquez | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.54M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 1.9¢ | $128.6K | 6.390M |
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3337643 | 1.9¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1075545 | 5 |
| Last trade - 15.57pm 13/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |
